Raya adds second ALS drug to U.K. platform trial
Raya Therapeutic says RT1972, also called cutamesine, will join RT1999 in the NIHR-funded EXPERTS-ALS platform trial led by the University of Sheffield and the University of Oxford. Both arms are expected to begin dosing in early to mid-2027, giving the company two clinical-stage ALS compounds in the same study.
Why it matters: - Raya now has two compounds in the same U.K. ALS platform trial, a stronger test of the company’s broader strategy to advance multiple disease-modifying candidates. - The trial is designed to quickly identify whether a drug is likely slowing ALS progression, which could move promising treatments into larger studies faster. - Results from RT1972 could also shape future development of the drug beyond ALS.
What happened: - Raya Therapeutic said RT1972 (cutamesine) has been added as a treatment arm in EXPERTS-ALS, the EXPErimental medicine Route To Success in ALS platform trial. - RT1999 (smilagenin) was already selected for the same trial in March 2026. - Raya expects both treatment arms to begin dosing their first patients in early to mid-2027. - The announcement was made Nov. 16, 2026.
The details: - EXPERTS-ALS is led by Professor Chris McDermott at the University of Sheffield and Professor Martin Turner at the University of Oxford. - The study includes about 17 clinical centres across the U.K. and is sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. - The trial is part of the broader portfolio of the U.K. MND Research Institute. - The National Institute for Health and Care Research funds the study through its Efficacy and Mechanism Evaluation programme and Biomedical Research Centre Capacity Building funding schemes. - Patient groups MND Association, My Name‘5 Doddie Foundation and the Darby Rimmer Foundation are providing additional support, along with medical research charity LifeArc. - Each trial arm is expected to enroll about 80 participants and treat them for six months. - The primary endpoint is blood neurofilament light chain, or NfL. - The study will also assess function, quality of life and target engagement. - Multiple interim analyses are built in to support rapid decision-making. - Drugs showing an early signal of disease modification can be prioritized for larger placebo-controlled trials. - RT1972 is an investigational, orally administered small molecule sigma-1 receptor agonist that crosses the blood-brain barrier. - The sigma-1 receptor is described as a chaperone protein involved in calcium signaling, cellular stress responses and mitochondrial functioning. - Raya says RT1972 is neuroprotective across multiple neurodegenerative disease models. - In the SOD1-G93A mouse model of ALS, RT1972 significantly extended survival. - In cellular models, RT1972 protected neuronal survival in a concentration-dependent manner, activated pro-survival Akt and ERK signaling, increased axonal outgrowth and protected against TDP-43 mislocalization. - RT1972 has been studied in Phase 1 and Phase 2 trials in healthy volunteers and in various central nervous system indications, where it was generally well-tolerated. - RT1999 is an investigational, orally administered small molecule that crosses the blood-brain barrier and acts as a neurotrophic factor modulator. - Raya said its team will be at Jefferies Healthcare/London Life Sciences Week from Nov. 16-19, 2026, to discuss the broader pipeline. - Raya says its pipeline includes five distinct clinical-stage compounds targeting different pathways involved in motor neuron degeneration in ALS.
Between the lines: - A second selection for EXPERTS-ALS gives Raya another independent scientific endorsement, not just of one asset but of its multi-asset pipeline approach. - The use of NfL as a primary endpoint means the trial is built for speed, since changes in the biomarker can appear within months rather than waiting for longer-term clinical outcomes. - The platform-trial design lowers friction for testing multiple candidates against the same infrastructure, which can accelerate go-or-no-go decisions.
What's next: - EXPERTS-ALS is expected to screen participants and generate interim readouts that could determine whether RT1972 advances to larger trials. - Raya will continue to work with the University of Sheffield, the University of Oxford and the EXPERTS-ALS team as the two treatment arms move toward first dosing in 2027. - The company said trial data will inform future clinical development of RT1972 for ALS and potentially other indications.
The bottom line: - Raya has turned one ALS trial slot into two, increasing the odds that at least one of its lead compounds shows a signal in a fast-moving U.K. platform study.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
50 States Today
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.